Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: A 4-week open-label parallel-group study

References

• Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord 2005; 86: 99–104
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. 1994. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Press.
   Google Scholar
• Amore M, Jori MC. Faster response on amisulpride 50 mg versus sertraline 50–100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 2001; 16: 317–324
   PubMed Web of Science ®Google Scholar
• Ananth J. Treatment-resistant depression. Psychother Psychosom 1998; 67: 61–70
   PubMed Web of Science ®Google Scholar
• Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993; 19: 609–618
   PubMed Web of Science ®Google Scholar
• Baghai TC, Moller HJ, Rupprecht R. Recent progress in pharmacological and non-pharmacological treatment options of major depression. Curr Pharm Des 2006; 12: 503–515
   PubMed Web of Science ®Google Scholar
• Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry 2004; 16: 189–194
   PubMedGoogle Scholar
• Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672–676
   PubMed Web of Science ®Google Scholar
• Bech P. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Int J Neuropsychopharmacol 2001; 4: 337–345
   PubMed Web of Science ®Google Scholar
• Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J Clin Psychiatry 2005; 66(Suppl 8)30–40
   PubMed Web of Science ®Google Scholar
• Bowles TM, Levin GM. Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother 2003; 37: 687–694
   PubMed Web of Science ®Google Scholar
• Browne S, Garavan J, Gervin M, Roe M, Larkin C, O'Callaghan E. Quality of life in schizophrenia: insight and subjective response to neuroleptics. J Nerv Ment Dis 1998; 186: 74–78
   PubMed Web of Science ®Google Scholar
• Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381–389
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE, Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351–1360
   PubMed Web of Science ®Google Scholar
• Carson WH (May, 2004) , Kitagawa H. 2004. Short-term efficacy of aripiprazol on depression and anxiety in schizophrenia. Poster presented at the 157th Annual Meeting of the American Psychiatric Association, New York, USA, 1–6 .
   Google Scholar
• Cassano GB, Jori MC. Efficacy and safety of amisulpride 50 mg versus paroxetine 20 mg in major depression: a randomized, double-blind, parallel group study. Int Clin Psychopharmacol 2002; 17: 27–32
   PubMed Web of Science ®Google Scholar
• De Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 1995; 10(Suppl 4)19–23
   PubMed Web of Science ®Google Scholar
• Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49: 538–544
   PubMed Web of Science ®Google Scholar
• Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin N Am 1996; 19: 179–200
   PubMed Web of Science ®Google Scholar
• Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998; 51: 267–285
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW. Aripiprazole. Expert Opin Pharmacother 2005; 6: 2091–2101
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004; 161: 564–566
   PubMed Web of Science ®Google Scholar
• Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 2003; 60: 974–977
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62
   PubMed Web of Science ®Google Scholar
• Hellerstein DJ. Aripiprazole as an adjunctive treatment for refractory major depression. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 1347–1348
   PubMed Web of Science ®Google Scholar
• Helmchen H, Hippius H. [Depression syndrome in the course of neuroleptic therapy]. Nervenarzt 1967; 38: 455–458
   PubMedGoogle Scholar
• Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002; 441: 137–140
   PubMed Web of Science ®Google Scholar
• Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63: 763–771
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003; 6: 325–337
   PubMed Web of Science ®Google Scholar
• Keck PE, Jr, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 1651–1658
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Lam RW. Enhancing outcomes in the management of treatment-resistant depression: a focus on atypical antipsychotics. Bipolar Disord 2003; 5(Suppl 2)36–47
   PubMedGoogle Scholar
• Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D, Pollmacher T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 2002; 35: 220–225
   PubMed Web of Science ®Google Scholar
• Kujawa M, Saha AR, Ingenito GG. Aripiprazole for long-term maintenance treatment of schizophrenia. Int J Neuropsychopharmacol 2002; 5(Suppl 1)186
   Google Scholar
• Lattanzi L, Dell'Osso L, Cassano P, Pini S, Rucci P, Houck PR, Gemignani A, Battistini G, Bassi A, Abelli M, Cassano GB. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002; 4: 307–314
   PubMed Web of Science ®Google Scholar
• Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 61: 123–136
   PubMed Web of Science ®Google Scholar
• McQuade R, Saha A, Ingenito G, Ali M, Archibald D. Aripiprazole for long-term maintenance treatment of schizophrenia. Eur Neuropsychopharmacol 2002; 12: S288
   Web of Science ®Google Scholar
• Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 1159–1172
   PubMed Web of Science ®Google Scholar
• Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J. Pharmacol Exp Ther 2000; 295: 853–861
   PubMed Web of Science ®Google Scholar
• Moller HJ. Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?. Eur Arch Psychiatry Clin Neurosci 2005; 255: 190–201
   PubMed Web of Science ®Google Scholar
• Nierenberg AA. Do some antidepressants work faster than others?. J Clin Psychiatry 2001; 62(Suppl 15)22–25
   PubMedGoogle Scholar
• Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999; 60: 256–259
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, Fava M, Nierenberg AA. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 2005; 66: 1326–1330
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, Fava M. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004; 65: 217–221
   PubMed Web of Science ®Google Scholar
• Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003; 64: 1048–1056
   PubMed Web of Science ®Google Scholar
• Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry 2005; 66: 148–158
   PubMed Web of Science ®Google Scholar
• Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681–690
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Weizman A. Mirtazapine for neuroleptic-induced akathisia. Am J Psychiatry 2001; 158: 819
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Epshtein S, Fuchs C, Schneidman M, Weizman R, Weizman A. Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol 2003; 23: 305–308
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. Biol Psychiatry 2006; 59: 1071–1077
   PubMed Web of Science ®Google Scholar
• Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs?. J Clin Psychiatry 2001; 62: 358–361
   PubMed Web of Science ®Google Scholar
• Ranjan S, Chandra PS, Chaturvedi SK, Prabhu SC, Gupta A. Atypical antipsychotic-induced akathisia with depression: therapeutic role of mirtazapine. Ann Pharmacother 2006; 40: 771–774
   PubMed Web of Science ®Google Scholar
• Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999; 60(Suppl 10)5–14
   PubMed Web of Science ®Google Scholar
• Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, bou-Gharbia N, Impellizzeri C, Kaplita S, Rollin L, Iwamoto T. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006; 20: 536–546
   PubMed Web of Science ®Google Scholar
• Schule C, Romeo E, Uzunov DP, Eser D, di MF, Baghai TC, Pasini A, Schwarz M, Kempter H, Rupprecht R. Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3alpha-hydroxysteroid dehydrogenase activity. Mol Psychiatry 2006; 11: 261–272
   PubMed Web of Science ®Google Scholar
• Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131–134
   PubMed Web of Science ®Google Scholar
• Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005; 66: 1216–1220
   PubMed Web of Science ®Google Scholar
• Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11–19
   PubMedGoogle Scholar
• Stahl SM, Nierenberg AA, Gorman JM. Evidence of early onset of antidepressant effect in randomized controlled trials. J Clin Psychiatry 2001; 62(Suppl 4)17–23
   PubMedGoogle Scholar
• Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003; 64(Suppl 19)6–12
   Google Scholar
• Stassen HH, Angst J, Delini-Stula A. Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses. Pharmacopsychiatry 1996; 29: 87–96
   PubMed Web of Science ®Google Scholar
• Szegedi A, Muller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 2003; 64: 413–420
   PubMed Web of Science ®Google Scholar
• Tatsumi M, Jansen K, Blakely RD, Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 1999; 368: 277–283
   PubMed Web of Science ®Google Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178: 234–241
   PubMed Web of Science ®Google Scholar
• Thompson C. Onset of action of antidepressants: results of different analyses. Hum Psychopharmacol 2002; 17(Suppl 1)S27–32
   Google Scholar
• Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079–1088
   PubMed Web of Science ®Google Scholar
• Vieta E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, bou-Gharbia N, Swanink R, Iwamoto T. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005; 187: 235–242
   PubMed Web of Science ®Google Scholar
• Wada T, Kanno M, Aoshima T, Otani K. Dose-dependent augmentation effect of bromocriptine in a case with refractory depression. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 457–462
   PubMed Web of Science ®Google Scholar
• Willner P, Hale AS, Argyropoulos S. Dopaminergic mechanism of antidepressant action in depressed patients. J Affect Disord 2005; 86: 37–45
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Wunderlich U, Zaudig M, Fydrich T. Strukturiertes Klinisches Interview für DSM-IV. Achse I: Psychische Störungen. Hogrefe, Göttingen 1997
   Google Scholar
• Worthington JJ III, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 2005; 20: 9–11
   PubMed Web of Science ®Google Scholar
• Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, Suppes T, Calabrese JR. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry 2005; 66(Suppl 5)40–48
   PubMed Web of Science ®Google Scholar
• Yokoi F, Grunder G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002; 27: 248–259
   PubMed Web of Science ®Google Scholar
• Zarate CA, Jr, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, Charney DS, Manji HK. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004; 56: 54–60
   PubMed Web of Science ®Google Scholar